This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Kadmon Holdings, Inc.

Drug Names(s): taribavirin hydrochloride, KD024

Description: Viramidine is a nucleoside (guanisine) analog prodrug of ribavirin. It is converted to ribavirin by the liver enzyme adenosine deaminase.

Ribavirin itself is a prodrug that is metabolized to the active 5'-monophosphate, -diphosphate and -triphosphate in vivo. Ribavirin 5'-monophosphate (RMP) inhibits cellular inosine monophosphate dehydrogenase (IMPDH), thereby depleting intracellular pools of GTP for viral replication. All the 5'-phosphate forms of ribavirin have been implicated as direct inhibitors of viral RNA polymerases.

Deal Structure: In June 2009, Valeant Pharmaceuticals entered into an exclusive option agreement with Schering-Plough for taribavirin in Japan. In exchange for the exclusive option, Schering-Plough has agreed to waive and release its last right of refusal on taribavirin under a 2000 agreement, providing more flexibility for Valeant to actively pursue partnering arrangements for the rest of the world. Under the terms of the option agreement, Valeant granted Schering-Plough the option to enter into an exclusive license agreement for the development and commercialization of taribavirin in Japan. Upon exercising the option and entering into the exclusive license agreement, Schering-Plough would provide a $2 million upfront payment to Valeant and pay mid-single digit royalties on net sales of taribavirin in Japan.

In November 2010, Valeant granted Kadmon an exclusive, worldwide license to taribavirin, excluding the territory of Japan, in exchange for an upfront payment of $5 million, other development...See full deal structure in Biomedtracker

Partners: Valeant Pharmaceuticals International, Inc.

Viramidine News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug